BPC-157 (Pentadecapeptide)

What Is BPC-157? Origin, Sequence and Evidence

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library2 min readLast reviewed 2026-08-294 cited sources

The short answer

BPC-157 (also written BPC157, BPC 157 or "BPC 157 peptide", and frequently mistyped as BCP157 or BP157) is a synthetic pentadecapeptide of fifteen residues, GEPPPGKPADDAGLV, 1419.5 Da, corresponding to a partial sequence of a protein found in human gastric juice. Unusually among research peptides, it has entered registered clinical development and a placebo-controlled Phase 2 trial is currently recruiting.

Key facts

Sequence
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Single-letter
GEPPPGKPADDAGLV
Length
15 residues (pentadecapeptide)
Molecular weight
1419.5 Da
Formula
C62H98N16O22
CAS number
137525-51-0
PubChem CID
9941957
Development codes
PL-14736, PLD-116, PL-10
Current trial
NCT07437547 (Phase 2, recruiting)

Where it comes from

BPC-157 corresponds to a partial sequence of body protection compound, a protein identified in human gastric juice by the research group at the University of Zagreb. The synthetic fifteen-residue peptide is not itself isolated from the stomach. It is a fragment of that protein's sequence, made by solid-phase synthesis. On this site it is supplied alone, co-lyophilised with GHK-Cu and TB-500 in the GLOW blend, and with KPV added in the KLOW blend.

What makes it structurally distinctive

Four of its fifteen residues are proline, three are glycine. That is an unusually high proportion of the two residues that most affect backbone flexibility: proline rigidifies, glycine liberates. The result is a peptide with alternating constrained and flexible regions and considerable resistance to peptidases, since proline-adjacent bonds are poor substrates for most of them.

Research material referenced

BPC-157 5mg, third-party HPLC tested

Buy BPC-157 · £16.95

The stability claim in its name

The literature routinely calls it the stable gastric pentadecapeptide. That is a specific claim: the Zagreb group reported it as stable in human gastric juice, which is an environment that destroys most peptides within minutes. If correct it is the compound's most unusual property, and the proline content is a plausible structural reason for it.

The clinical development most coverage omits

BPC-157 entered clinical development as PL-14736 for inflammatory bowel disease, reported by Sikirić and colleagues in Inflammopharmacology in 2006. A Phase 1 safety and pharmacokinetics study in 42 healthy volunteers was registered as NCT02637284. And a randomised, double-blind, placebo-controlled Phase 2 trial in acute hamstring muscle strain, NCT07437547, began recruiting on 2 February 2026 with 120 participants and primary completion due 14 February 2027.

Why that matters for how the evidence reads

Most research peptides have no registered interventional trials at all; DSIP has none, Selank and Semax have none in the West. BPC-157 having entered formal clinical development, and having a placebo-controlled Phase 2 underway now, puts it in a different evidential position. It does not make it a treatment for anything, and no result exists yet, but the distinction is real.

Regulatory position

BPC-157 holds no marketing authorisation from the MHRA, EMA or FDA. A recruiting trial is not an approval and says nothing about outcome. It is supplied here for laboratory research only, and material supplied for research has no relationship to any registered trial.

Frequently asked questions

Is BPC-157 in clinical trials?

Yes. NCT07437547 is a randomised, double-blind, placebo-controlled Phase 2 trial in acute hamstring strain, recruiting since February 2026 with 120 participants. A Phase 1 study was registered as NCT02637284.

Is BPC-157 found in the stomach?

It corresponds to a partial sequence of a protein identified in human gastric juice. The peptide itself is synthesised, not isolated.

Is it approved anywhere?

No. It holds no marketing authorisation in any jurisdiction, and an ongoing trial is not an approval.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More BPC-157 (Pentadecapeptide) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.